NovoCure
Zug
About NovoCure
Novocure™ is dedicated to the development of tumor treating fields therapy (NovoTTF™ Therapy), a new weapon for patients and physicians in the battle against cancer. NovoTTF Therapy is a novel anti-mitotic treatment that has been shown to slow or reverse tumor progression by inducing cell death in certain solid tumors. The company pioneered the concept that the electric properties of cells can be used as an effective target for an anti-neoplastic therapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $500K – $1M
- Total funding: $1.0B
- Funding stage: IPO
- Last round: Post-IPO Debt (May 2024)
- Ticker: nasdaq:NVCR
- Website: novocure.com
- Phone: +1 603 436 2809
Industries & Categories
Biotechnology, Health Care, Medical Device, Oncology
Social Profiles
Canonical: https://fsome.com/organization/novocure-2899 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.